Environmental Monitoring in a Class D Pharmaceutical Facility: Microbial Load and Hygiene Practices, a Risk-Based Cross-Sectional Study
Downloads
DOI:
https://doi.org/10.71079/ASIDE.HS.100725170Abstract
Background: Environmental monitoring is a crucial current Good Manufacturing Practice (cGMP) tool for assessing the status of the working environment in a Pharmaceutical Manufacturing Facility.
Methods: The test was conducted between May 20 and 25, 2025. 90 mm Diameter Settle Plates methods, 4 hours exposure under dynamic conditions, were used as a test method to study the microbial load in controlled and classified areas. The finger dab test was used to assess hygiene and sanitization practices in the plant. The non-viable count was excluded from the study due to limitations, including a lack of facilities for conducting the tests.
Result: The result of the environmental monitoring test was below 100 colony-forming units (CFU) in the rooms. The mean value of Total Aerobic Microbial Count and Total Yeast and Mold Count shows a higher microbial count at the Near Return air loop. The p-value of Total aerobic microbial count and Total Yeast and Mold Count was found to be 0.8685 and 0.8716, respectively. The result is not significant at p<0.05. The result of the Finger dab test was below 100 CFU/5 fingerprints in both hands and complies with the internal action limit.
Conclusion: The result of the study suggests that the higher load of organisms was found at the “near return loop area”. The result of the Finger dab test was satisfactory according to the in-house limit (100 CFU). The result can serve as a basis for selecting a sample spot for regular Environmental Monitoring in a Manufacturing Facility.
Keywords:
Environment Monitoring Test, Near Return Air Loop, Clean rooms, Finger Dab TestReferences
1. Sandle T, Tidswell W, Saghee MR. Microbiology and sterility assurance in pharmaceuticals and medical devices2011:
2. Organization WH. WHO good manufacturing practices for sterile pharmaceutical products. WHO Technical Report Series, No. 961, Annex 6. Geneva: World Health Organization, 2011.
3. Ratajczak M, Kubicka MM, Kaminska D, Sawicka P, Dlugaszewska J. Microbiological quality of non-sterile pharmaceutical products. Saudi Pharm J. 2015: 303 [PMID: 26106278, https://doi.org/10.1016/j.jsps.2014.11.015] DOI: https://doi.org/10.1016/j.jsps.2014.11.015
4. Mehdi A, Mehmood M, Usman Ghani M, Ghani, Ismail M, Ameen F. Environmental Monitoring and Risk Assessment of Cleanrooms within Pharmaceutical Industry. International Journal of Pharmacy. 2018: 38
5. Sandle T. The use of a risk assessment in the pharmaceutical industry – the application of FMEA to a sterility testing isolator: a case study. European Journal of Parenteral and Pharmaceutical Sciences. 2003: 43
6. Whyte W, Eaton T. Microbiological contamination models for use in risk assessment during pharmaceutical production. European Journal of Parenteral and Pharmaceutical Sciences. 2004: 11
7. Whyte W, Eaton T. Microbial risk assessment in pharmaceutical cleanrooms. European Journal of Parenteral and Pharmaceutical Sciences. 2004: 16
8. Singh SK, Dutta K, Chaudhary R. Risk Based Study of Sample Spot Fixing for Conducting Environmental Monitoring Test in Classified Areas of Pharmaceutical Industry. Assessment (QMRA). 11
Data Availability Statement
No datasets were generated or analyzed for this study beyond the summary results presented in the article; therefore, no additional data are available. Data sharing does not apply to this research. For reasonable queries about the summarized results or methods, please contact the corresponding author listed in the manuscript.
License
Copyright (c) 2025 Shrawan Singh

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright in their work and grant the publisher a non-exclusive right of first publication.
Downloads
Published
Issue
Section
How to Cite
Article history
- Received
- 10 Jul 2025
- Received in revised form
- 24 Sep 2025
- Accepted
- 26 Sep 2025
- Published
- 7 Oct 2025